Statin therapy was associated with a significantly reduced restenosis rate (28.6% vs 50.9%, P=0.01) and fewer major adverse coronary events at 6 months post-stenting in Pl(A2) allele carriers.
Cohort (n=650)
Does statin therapy reduce restenosis rates and major adverse coronary events in patients with the Pl(A2) allele following coronary stent implantation?
Statin therapy abrogates the increased risk of restenosis and adverse clinical outcomes associated with the Pl(A2) polymorphism after coronary stenting.
Absolute Event Rate: 28.6% vs 50.9%
p-value: p=0.01
Aims Platelets play a central role in the restenosis process by inducing neointimal proliferation after coronary interventions. Glycoprotein IIb/IIIa Pl(A2)polymorphism has been associated with the occurrence of acute coronary syndromes and increased restenosis rates. Statins have been shown to exert potent antiproliferative, antiinflammatory and antithrombotic properties, thereby potentially interfering with the major processes of in-stent restenosis. Therefore, we sought to find out whether statin therapy interferes with restenosis and clinical outcome at 6 months following successful coronary stent implantation in the presence or absence of the Pl(A2)allele. Methods and Results Six hundred and fifty consecutive patients were followed for 6 months after coronary stent insertion. Carriers of the Pl(A2)allele demonstrated a significantly increased restenosis rate, which was abrogated by statin therapy (50.9% vs 28.6%, P=0.01). Moreover, statin therapy was associated with a significant reduction (28.2% vs 49.3%, P<0.01) in the occurrence of major adverse coronary events (myocardial infarction, cardiac death, target vessel revascularization) in the 6 months after the intervention in patients with the Pl(A2)allele. Conclusion Statin therapy reduces increased stent restenosis rates and improves clinical outcome following coronary stent implantation in patients bearing the Pl(A2)allele, suggesting that statins interfere with the functional consequence of a genetically determined platelet-mediated risk factor associated with Pl(A2)polymorphism.
Dirk Walter (2001) conducted a cohort in Coronary stent implantation (n=650). Statin therapy vs. No statin therapy was evaluated on Restenosis rate in carriers of the Pl(A2) allele (p=0.01). Statin therapy was associated with a significantly reduced restenosis rate (28.6% vs 50.9%, P=0.01) and fewer major adverse coronary events at 6 months post-stenting in Pl(A2) allele carriers.